ABVC BioPharma, Inc. (ABVC): Price and Financial Metrics
GET POWR RATINGS... FREE!
ABVC Stock Summary
- With a one year PEG ratio of 0.47, ABVC BIOPHARMA INC is expected to have a higher PEG ratio (a measure of how expensive a stock is relative to its expected earnings growth) than just 4.24% of US stocks.
- ABVC's went public 1.48 years ago, making it older than just 2.75% of listed US stocks we're tracking.
- With a price/sales ratio of 72.4, ABVC BIOPHARMA INC has a higher such ratio than 96.97% of stocks in our set.
- Stocks with similar financial metrics, market capitalization, and price volatility to ABVC BIOPHARMA INC are SII, SOS, LTH, ZETA, and LFST.
- Visit ABVC's SEC page to see the company's official filings. To visit the company's web site, go to www.ambrivis.com.
ABVC Valuation Summary
- In comparison to the median Healthcare stock, ABVC's price/earnings ratio is 105.73% lower, now standing at -1.3.
- ABVC's price/sales ratio has moved down 44.9 over the prior 18 months.
Below are key valuation metrics over time for ABVC.
| Stock | Date | P/S | P/B | P/E | EV/EBIT |
|---|---|---|---|---|---|
| ABVC | 2023-01-20 | 74.3 | 4.3 | -1.3 | -1.4 |
| ABVC | 2023-01-19 | 74.3 | 4.3 | -1.3 | -1.4 |
| ABVC | 2023-01-18 | 72.9 | 4.2 | -1.3 | -1.4 |
| ABVC | 2023-01-17 | 77.6 | 4.5 | -1.4 | -1.5 |
| ABVC | 2023-01-13 | 82.2 | 4.8 | -1.4 | -1.6 |
| ABVC | 2023-01-12 | 88.6 | 5.1 | -1.6 | -1.7 |
ABVC Stock Price Chart Interactive Chart >
ABVC Price/Volume Stats
| Current price | $0.72 | 52-week high | $3.13 |
| Prev. close | $0.73 | 52-week low | $0.50 |
| Day low | $0.71 | Volume | 60,994 |
| Day high | $0.76 | Avg. volume | 2,446,175 |
| 50-day MA | $0.75 | Dividend yield | N/A |
| 200-day MA | $1.09 | Market Cap | 23.54M |
ABVC BioPharma, Inc. (ABVC) Company Bio
American BriVision (Holding) Corporation, a clinical stage biopharmaceutical company, develops drugs and medical devices to fulfill unmet medical needs in the United States. The company is developing ABV-1501, a combination therapy for triple negative breast cancer; ABV-1504 for major depressive disorders; ABV-1505 for attention deficit hyperactivity disorder; ABV-1703 for the treatment of pancreatic cancer; ABV-1702 to treat myelodysplastic syndromes; ABV-1601 for treating depression in cancer patients; and ABV-1701 Vitargus for the treatment of retinal detachment or vitreous hemorrhage. It has a co-development agreement with Rgene Corporation; and collaboration agreements with BioHopeKing Corporation and BioFirst Corporation. The company was incorporated in 2015 and is based in Fremont, California. American BriVision (Holding) Corporation is a subsidiary of YuanGene Corporation.
Latest ABVC News From Around the Web
Below are the latest news stories about ABVC BIOPHARMA INC that investors may wish to consider to help them evaluate ABVC as an investment opportunity.
ABVC BioPharma ABV-1505 ADHD Phase IIa Results Presented at 2023 APSARD ConferenceFREMONT, CA, Jan. 19, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire – ABVC BioPharma, Inc. (NASDAQ: ABVC), a clinical stage biopharmaceutical company developing therapeutic solutions in oncology/hematology, CNS, and ophthalmology, today announced that Dr. Keith McBurnett, Professor of Psychiatry at the University of California San Francisco, presented the results of the Phase IIa study of its medical treatment, ABV-1505 ADHD, on January 14, 2023 at the 2023 Conference of The American Professional So |
ABVC: Several Potential Paths to Achieving Near-Term MilestonesBy M. Marin NASDAQ:ABVC READ THE FULL ABVC RESEARCH REPORT Several potential paths to near-term milestones… ABVC BioPharma (NASDAQ:ABVC), a biopharma and medical device company developing therapies for a range of conditions focused on oncology/hematology, central nervous system (CNS) and ophthalmology, has several potential paths to achieving near-term milestones as it advances its portfolio of |
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on FridayThe final day of trading this week is here and we're starting it off with a look at the biggest pre-market stock movers for Friday! |
FDA Approves IND Submission Allowing ABVC BioPharma to Proceed With Clinical Study of ABV-1519 for Treatment of Non-Small Cell Lung CancerFREMONT, CA, Jan. 05, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire – ABVC BioPharma, Inc. (NASDAQ: ABVC), a clinical stage biopharmaceutical company developing therapeutic solutions in oncology/hematology, CNS, and ophthalmology today announced that the US Food & Drug Administration notified the company that the IND application for the proposed clinical investigation of BLEX 404, the primary active ingredient in ABV-1519, for advanced inoperable or metastatic EGFR-mutated non-small cell lung cancer |
ABVC: Key Medical Venues Participating in Clinical StudiesBy M. Marin NASDAQ:ABVC READ THE FULL ABVC RESEARCH REPORT Adding venues and enrolling patients to advance assets … ABVC BioPharma (NASDAQ:ABVC), a biopharma and medical device company developing therapies for a range of conditions focused on oncology/hematology, central nervous system (CNS) and ophthalmology, continues to advance its clinical studies and add important medical centers. UCSF |
ABVC Price Returns
| 1-mo | 15.20% |
| 3-mo | -5.26% |
| 6-mo | 6.87% |
| 1-year | -71.20% |
| 3-year | N/A |
| 5-year | N/A |
| YTD | 15.20% |
| 2022 | -81.56% |
| 2021 | -33.53% |
| 2020 | 16.70% |
| 2019 | -87.86% |
| 2018 | N/A |
Loading social stream, please wait...